Literature DB >> 12722852

Osteoporosis in men.

Jant M Campion1, Michael J Maricic.   

Abstract

Osteoporosis in men is now recognized as an increasingly important public health issue. About 30 percent of hip fractures occur in men, and one in eight men older than 50 years will have an osteoporotic fracture. Because of their greater peak bone mass, men usually present with hip, vertebral body, or distal wrist fractures 10 years later than women. Hip fractures in men, however, result in a 31 percent mortality rate at one year after fracture versus a rate of 17 percent in women. Major risk factors for osteoporosis in men are glucocorticoid use for longer than six months, osteopenia seen on plain radiographs, a history of nontraumatic fracture, hypogonadism, and advancing age. Bisphosphonates and teriparatide (recombinant parathyhroid hormone) have recently been approved for use in men and should be considered along with supplemental calcium and vitamin D. Increased awareness by physicians of risk factors for male osteoporosis--and early diagnosis and treatment--are needed to decrease the morbidity and mortality resulting from osteoporotic fractures.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12722852

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  34 in total

1.  Bone mineral density of the spine and femur in healthy Saudis.

Authors:  M Salleh M Ardawi; Abdulraouf A Maimany; Talal M Bahksh; Hasan A N Nasrat; Waleed A Milaat; Raja M Al-Raddadi
Journal:  Osteoporos Int       Date:  2004-05-27       Impact factor: 4.507

Review 2.  The treatment of late-onset hypogonadism.

Authors:  Oktay Üçer; Bilal Gümüş
Journal:  Turk J Urol       Date:  2014-03-24

3.  Effect of monthly ibandronate on hip structural geometry in men with low bone density.

Authors:  H K Genant; E M Lewiecki; T Fuerst; M Fries
Journal:  Osteoporos Int       Date:  2011-08-03       Impact factor: 4.507

4.  Reconsideration of the relevance of mild wedge or short vertebral height deformities across a broad age distribution.

Authors:  W Yu; Q Lin; X Zhou; H Shao; P Sun
Journal:  Osteoporos Int       Date:  2014-07-29       Impact factor: 4.507

5.  Effect of fitness and physical activity on bone mass in adolescents: the HELENA Study.

Authors:  L Gracia-Marco; G Vicente-Rodríguez; J A Casajús; D Molnar; M J Castillo; L A Moreno
Journal:  Eur J Appl Physiol       Date:  2011-03-11       Impact factor: 3.078

6.  Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial.

Authors:  Jason R Westin; Michael A Thompson; Vince D Cataldo; Luis E Fayad; Nathan Fowler; Michelle A Fanale; Saatva Neelapu; Felipe Samaniego; Jorge Romaguera; Jatin Shah; Peter McLaughlin; Barbara Pro; Larry W Kwak; Perpetua Sanjorjo; William A Murphy; Camillo Jimenez; Bela Toth; Wenli Dong; Fredrick B Hagemeister
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-12-29

7.  Adiposity and bone health in Spanish adolescents. The HELENA study.

Authors:  L Gracia-Marco; F B Ortega; D Jiménez-Pavón; G Rodríguez; M J Castillo; G Vicente-Rodríguez; L A Moreno
Journal:  Osteoporos Int       Date:  2011-05-12       Impact factor: 4.507

8.  Clinical and laboratory evaluation of idiopathic male infertility in a secondary referral center in India.

Authors:  Shadaan Abid; Anurupa Maitra; Pervin Meherji; Zareen Patel; Seema Kadam; Jatin Shah; Rupin Shah; Vijay Kulkarni; V Baburao; Jyotsna Gokral
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

9.  Osteoporosis screening for men: are family physicians following the guidelines?

Authors:  Natalie Cheng; Michael E Green
Journal:  Can Fam Physician       Date:  2008-08       Impact factor: 3.275

10.  Bone fragility in male glucocorticoid-induced osteoporosis is not defined by bone mineral density.

Authors:  K Hayashi; M Yamamoto; Y Murakawa; M Yamauchi; H Kaji; T Yamaguchi; T Sugimoto
Journal:  Osteoporos Int       Date:  2009-04-22       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.